Ardelyx is a commercial-stage biopharmaceutical company focused on the development and commercialization of medicines for unmet medical needs. The company markets two therapies derived from the active ingredient tenapanor, a sodium/hydrogen exchanger (NHE3) inhibitor. IBSRELA is approved in the U.S. for the treatment of adults with irritable bowel syndrome with constipation, while XPHOZAH is approved to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx is also developing a next-generation NHE3 inhibitor intended for application across multiple therapeutic areas. The company serves the U.S. market primarily through its own commercial organization, which includes a specialty sales force and patient services programs such as ArdelyxAssist. Ardelyx has established collaborations with industry partners to commercialize its products in territories outside the United States. The company was founded in October 2007.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage ardelyx.com
Sector Healthcare IR page ir.ardelyx.com
Tags
gastroenterology, nephrology, irritable bowel syndrome, chronic kidney disease, hyperphosphatemia, oral small molecule, nhe3 inhibitor, specialty pharmaceuticals, IBSRELA, XPHOZAH, tenapanor, ArdelyxAssist
Press page —

Metrics

Valuation  
Market cap $ 858.525M
Market cap (USD) $ 858.525M
P/E -15.48
PEG —
P/BV 5.23
P/S 1.83
P/OCF -55.34
P/FCF -53.80
Dividend yield —
Turnover / mcap —
Returns  
ROE -36.2%
ROI -16.7%
ROIC -8.3%
Profit margin -15.1%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 153.8%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 19
Quality score -47.1%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 407.32M 333.615M 124.456M 52.158M 10.097M 7.571M 5.281M 2.607M 42M — 24.026M 31.623M 28.928M
Net profit -61.599M -39.136M -66.067M -67.207M -158.165M -94.313M -94.94M -91.298M -64.339M -112.387M -29.621M -3.214M -6.564M
Free cash flow -43.975M -45.82M -90.061M -70.099M -154.418M -81.759M -76.809M -70.585M -67.545M -97.4M -75.294M 11.541M 1.533M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 5.83 5.07 6.2 2.85 1.1 6.47 7.51 1.79 6.6 14.2 18.12 18.89 —
Price performance 12m 0.15 -0.18 1.18 1.59 -0.83 -0.14 3.19 -0.73 -0.54 -0.22 -0.04 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — — 0.00 502,000 7.73M 22M 57.7M 71.8M
↳ YoY growth +1,440.4% +184.9% +161.9% +24.5%
Borrowings, current (USD) — — — — — 32.3M — — — —
Lease liabilities (USD) — — — 4.68M 2.53M 13.2M 9.75M 6.16M 2.59M 5.12M
Cash and deposits (USD) 74.6M 75.4M 78.8M 181M 91M 72.4M 96.1M 21.5M 64.9M 68M
Right-of-use assets (USD) — — — 3.97M 2.27M 12.8M 9.3M 5.59M 2.38M 4.8M
Net debt (borrowings + leases - cash) (USD) — — — — — -26.9M — — — —
Cash flow detail
Operating cash flow (USD) -92.5M -65.2M -70.3M -76.5M -81.4M -153M -70M -89.7M -44.8M -42.5M
Purchases of property, plant and equipment (USD) -4.87M -2.36M -311,000 -325,000 -324,000 -1.87M -55,000 -344,000 -1.01M -1.49M
Change in receivables (cash effect) (USD) — -10.8M 10.7M 85,000 0.00 -502,000 -7.23M -14.3M -35.7M -14.1M
Change in inventories (cash effect) (USD) — — — — 0.00 0.00 -28.3M -21.1M -41.7M -31.9M
Change in payables (cash effect) (USD) 2.15M -1.03M -2.73M 39,000 3.44M -1.35M 6.58M 279,000 4.86M 3.24M
Interest paid (cash effect) (USD) — — -3.07M -4.92M -4.2M -3.47M -2.9M -4.24M -11.4M -15.7M
Income taxes paid (cash effect) (USD) — -3,000 -4,000 -2,000 -1,000 -4,000 -6,000 -51,000 -266,000 -485,000
Share-based compensation (USD) 5.32M 9.59M 9.23M 9.94M 10.6M 12M 10.8M 13.5M 37.4M 49M
Operating cash flow before change in receivables (USD) — -54.4M -81M -76.6M -81.4M -152M -62.8M -75.4M -9.14M -28.3M
Free cash flow (OCF - PPE - intangibles) (USD) -97.4M -67.5M -70.6M -76.8M -81.8M -154M -70.1M -90.1M -45.8M -44M
Income detail
Research and development expense (USD) 94.2M 75.5M 69.4M 71.7M 65.1M 91.1M 35.2M 35.5M 52.3M 71.5M
↳ 5y CAGR +49.3% +19.8% +22.6% +10.3% -0.7% -14.2% -12.5% -6.1% +1.9%
Total comprehensive income (USD) -112M -64.3M -91.3M -94.9M -94.3M -158M -67.3M -65.8M -39.3M -61.5M
Comprehensive income to owners (USD) -112M -64.3M -91.3M -94.9M -94.3M -158M -67.3M -65.8M -39.3M -61.5M
Provision for credit losses (USD) — 0.00 0.00 0.00 — — — — — —
Reported Feb 17, 2017 Mar 6, 2019 Mar 8, 2021 Mar 8, 2021 Mar 2, 2023 Mar 2, 2023 Mar 2, 2023 Feb 22, 2024 Feb 20, 2025 Feb 19, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 3, 2026

PDF Version

Trial fully enrolled ahead of schedule

Topline data expected in the second half of 2027

WALTHAM, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced that it has fully enrolled ahead of schedule all patients in the Phase 3 ACCEL clinical trial evaluating the safety and efficacy of IBSRELA® (tenapanor) for the treatment of chronic idiopathic constipation (CIC) in adults. Topline data is expected in the second half of 2027.

“Completing enrollment ahead of schedule in our Phase 3 clinical trial marks an important milestone for the Company,” said Michael Raab, President and Chief Executive Officer of Ardelyx. “The interest and pace of enrollment in the trial underscores the enthusiasm on the part of treating physicians for a new option for their patients experiencing the significant burden of CIC. We are grateful to the patients, the clinical teams and investigators at our trial sites whose commitment made this milestone possible. We look forward to sharing topline results in 2027.”

“Many CIC patients continue to experience symptoms despite available therapies, indicating the need for additional treatment options that provide sustained, meaningful relief,” said Rajani Dinavahi, M.D., Chief Medical Officer of Ardelyx. “Evaluating the use of IBSRELA for patients with CIC is an important objective for Ardelyx. CIC can impose a substantial burden on daily life, particularly after cycling through multiple over the counter and prescription treatments.”

ACCEL is a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial designed to assess the safety and efficacy of IBSRELA for the treatment of CIC in adults when administered twice daily for 26 consecutive weeks. The primary endpoint will assess the durable efficacy of tenapanor in relieving constipation. The Phase 3 ACCEL clinical trial in CIC is part of Ardelyx’s efforts to evaluate the potential of IBSRELA and its differentiated mechanism of action in a broader population of adult patients with constipation-related disorders. IBSRELA is currently approved in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. IBSRELA is not approved for the treatment of CIC.

Ardelyx recently presented the design and rationale for ACCEL at the American College of Gastroenterology (ACG) Annual Scientific Meeting. The presentation highlighted post hoc analyses of two Phase 3 studies of tenapanor in adults with IBS-C that, together with the recognized symptom continuum between CIC and IBS-C, supported further evaluation of tenapanor in adults with CIC.

About Chronic Idiopathic Constipation

CIC can impose a substantial burden on daily life, which is often the motivation for patients to seek care. Symptoms extend beyond infrequent bowel movements and can include discomfort, straining and bloating –which thought leaders in gastroenterology express as the most difficult symptom to treat. Patients often cycle through multiple over-the-counter treatments before seeking clinical care from their healthcare providers. Some patients continue to experience symptoms despite available therapies, indicating that there remains a need for additional treatment options that provide sustained, meaningful relief with acceptable tolerability. IBSRELA’s mechanism of action is being investigated now to understand the impact this therapy can have for individuals living with this condition.

About IBSRELA® (tenapanor)

IBSRELA® (tenapanor) is a locally acting inhibitor of the sodium/hydrogen exchanger 3 (NHE3), an antiporter expressed on the apical surface of the small intestine and colon that is primarily responsible for the absorption of dietary sodium. By inhibiting NHE3, tenapanor reduces the absorption of sodium from the small intestine and colon, retaining luminal water content, accelerating intestinal transit time and resulting in a softer stool consistency. IBSRELA has also been shown to reduce abdominal pain by decreasing visceral hypersensitivity and intestinal permeability in animal models. Please see additional full Prescribing Information.

IMPORTANT SAFETY INFORMATION (IBSRELA)

| WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS IBSRELA is contraindicated in patients less than 6 years of age; in nonclinical studies in young juvenile rats administration of tenapanor caused deaths presumed to be due to dehydration. Avoid use of IBSRELA in patients 6 years to less than 12 years of age. The safety and effectiveness of IBSRELA have not been established in patients less than 18 years of age. |

CONTRAINDICATIONS

  • IBSRELA is contraindicated in patients less than 6 years of age due to the risk of serious dehydration.

  • IBSRELA is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.

WARNINGS AND PRECAUTIONS Risk of Serious Dehydration in Pediatric Patients

  • IBSRELA is contraindicated in patients below 6 years of age. The safety and effectiveness of IBSRELA in patients less than 18 years of age have not been established. In young juvenile rats (less than 1 week old; approximate human age equivalent of less than 2 years of age), decreased body weight and deaths occurred, presumed to be due to dehydration, following oral administration of tenapanor. There are no data available in older juvenile rats (human age equivalent 2 years to less than 12 years).

  • Avoid the use of IBSRELA in patients 6 years to less than 12 years of age. Although there are no data in older juvenile rats, given the deaths in younger rats and the lack of clinical safety and efficacy data in pediatric patients, avoid the use of IBSRELA in patients 6 years to less than 12 years of age.

Diarrhea Diarrhea was the most common adverse reaction in two randomized, double-blind, placebo-controlled trials of IBS-C. Severe diarrhea was reported in 2.5% of IBSRELA-treated patients. If severe diarrhea occurs, suspend dosing and rehydrate patient.

MOST COMMON ADVERSE REACTIONS The most common adverse reactions in IBSRELA-treated patients (incidence ≥2% and greater than placebo) were: diarrhea (16% vs 4% placebo), abdominal distension (3% vs <1%), flatulence (3% vs 1%) and dizziness (2% vs <1%).

INDICATION IBSRELA (tenapanor) is indicated for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adults.

Please see fullPrescribing Information, including Boxed Warning, for additional risk information.

About Ardelyx

Ardelyx is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). The company’s pipeline includes the Phase 3 development of IBSRELA for chronic idiopathic constipation (CIC) and RDX10531, a next-generation NHE3 inhibitor with potential application across multiple therapeutic areas. Ardelyx works with its partners to develop and commercialize its products outside of the United States. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.

Forward-Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Ardelyx, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Litigation Reform Act of 1995, including Ardelyx’s current expectations regarding: the timing of topline data from the Phase 3 ACCEL clinical trial; and the potential of IBSRELA (tenapanor) to treat CIC and expand the patient population who may benefit from IBSRELA, subject to regulatory approval. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control and that could cause actual outcomes or results to differ materially from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, uncertainties associated with the development of, regulatory process for, and commercialization of drugs in the U.S. and internationally; the risk of delays in clinical trial completion, data analysis or reporting; the risk that clinical trial results may not establish sufficient safety and efficacy to support regulatory approval, including for CIC; and the risk that prior clinical results or post hoc analyses in IBS-C may not be predictive of results in CIC. Ardelyx undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ardelyx’s business in general, please refer to Ardelyx's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2026, and its future current and periodic reports to be filed with the Securities and Exchange Commission

Investor Contact: Lisa Caperelli SVP, Investor Relations & Corporate Communications [email protected]

Media Contact: Lindsey Manuel Associate Director, Corporate Communications [email protected]

Primary Logo

November 3, 2026

PDF Version

Q3 2026 total product revenue of $125.5 million, reflecting 19% growth year-over-year

IBSRELA Q3 2026 revenue growth of 23% year-over-year to $96.3 million

Strong financial position with $285.3 million in cash, cash equivalents and investments as of September 30, 2026

Enrollment completed ahead of schedule in Phase 3 Clinical Trial in CIC

Conference call scheduled for 4:30 PM Eastern Time

WALTHAM, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today reported financial results for the third quarter ended September 30, 2026, and provided a business update.

“Our third quarter results reflect the strength of the foundation we’ve built,” said Mike Raab, President and Chief Executive Officer of Ardelyx. “IBSRELA year-over-year growth of 23% is the engine driving total product revenue of over $125 million for the quarter. With our robust tenapanor intellectual property portfolio, and our fully enrolled Phase 3 ACCEL trial for CIC, the value of IBSRELA continues to strengthen. Finally, with over $285 million in cash and investments, and a disciplined capital allocation strategy, we are well positioned to create and deliver significant long-term value.”

Product Revenue Revenue for IBSRELA® (tenapanor) during the third quarter of 2026 was $96.3 million, reflecting year-over-year growth of 23%. The growth was driven by increases in total writers and total prescriptions.

Revenue for XPHOZAH® (tenapanor) during the third quarter of 2026 was $29.2 million, reflecting year-over-year growth of 7%.

2026 Full-Year Guidance and Outlook

  • Full-year 2026 revenue guidance for IBSRELA reiterated to be between $350 and $370 million.

  • Full-year 2026 revenue guidance for XPHOZAH reiterated to be between $110 and $120 million.

  • Full-year 2026 operating expense guidance reiterated to be below $500 million.

  • IBSRELA long-term guidance of achieving $1 billion in annual revenue remains.

Pipeline Updates

  • The Company has completed enrollment ahead of schedule in its Phase 3 clinical trial, ACCEL, evaluating tenapanor for the treatment of chronic idiopathic constipation (CIC) in adults. The Company is on track to announce topline data in the second half of 2027.

Corporate Updates

  • The United States Patent and Trademark Office notified the Company that on November 10, 2026, they will issue U.S. Patent No. 12,788,750 titled, “Oral Formulation of a Therapeutic Compound”, with an expiration date of December 6, 2041. This patent will cover the Company’s commercial formulations of both IBSRELA and XPHOZAH.

  • In October at the American College of Gastroenterology annual scientific meeting, the Company presented real world data showing that gastrointestinal-related healthcare resource utilization dropped after adults with IBS-C started IBSRELA.

  • Also in October, at the American Society of Nephrology Kidney meeting, the Company presented real-world data showing reductions in serum phosphate following XPHOZAH initiation in adults on dialysis with or without phosphate binders.

Third Quarter 2026 Financial Results

  • Cash Position: As of September 30, 2026, the Company had total cash, cash equivalents and short-term investments of $285.3 million, compared to total cash, cash equivalents and short-term investments of $264.7 million as of December 31, 2025.

  • **Revenues:**Total product revenue for the quarter ended September 30, 2026 was $125.5 million, compared to $105.5 million for the quarter ended September 30, 2025, reflecting 19% growth, driven by increased demand.

  • R&D Expenses: Research and development expenses were $25.2 million for the quarter ended September 30, 2026, compared to $18.1 million for the quarter ended September 30, 2025. The increase was primarily related to investments in the ACCEL Phase 3 trial for CIC.

  • SG&A Expenses: Selling, general and administrative expenses were $93.9 million for the quarter ended September 30, 2026, compared to $83.6 million for the quarter ended September 30, 2025. The increase was related to deliberate investments to address the access barriers and drive future adoption of IBSRELA.

  • Net Loss: Net loss for the quarter ended September 30, 2026 was $0.7 million, or $(0.00) per share, compared to net loss of $1.0 million, or $(0.00) per share, for the quarter ended September 30, 2025. The net loss for the third quarter of 2026 included share-based compensation expense of $15.1 million.

Conference Call Details The company will host a conference call today, November 3, 2026, at 4:30 PM ET to discuss today’s announcement. To participate in the conference call, please dial (877) 346-6112 (domestic) or +1 (848) 280-6350 (international) and ask to be joined into the Ardelyx call. A webcast of the call can also be accessed by visiting the Investor page of the company’s website, https://ardelyx.com/, and will be available on the website following the call.

IMPORTANT SAFETY INFORMATION (IBSRELA)

| WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS | |

| IBSRELA is contraindicated in patients less than 6 years of age; in nonclinical studies in young juvenile rats administration of tenapanor caused deaths presumed to be due to dehydration. Avoid use of IBSRELA in patients 6 years to less than 12 years of age. The safety and effectiveness of IBSRELA have not been established in patients less than 18 years of age. |

| |

CONTRAINDICATIONS

  • IBSRELA is contraindicated in patients less than 6 years of age due to the risk of serious dehydration.

  • IBSRELA is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.

WARNINGS AND PRECAUTIONS Risk of Serious Dehydration in Pediatric Patients

  • IBSRELA is contraindicated in patients below 6 years of age. The safety and effectiveness of IBSRELA in patients less than 18 years of age have not been established. In young juvenile rats (less than 1 week old; approximate human age equivalent of less than 2 years of age), decreased body weight and deaths occurred, presumed to be due to dehydration, following oral administration of tenapanor. There are no data available in older juvenile rats (human age equivalent 2 years to less than 12 years).

  • Avoid the use of IBSRELA in patients 6 years to less than 12 years of age. Although there are no data in older juvenile rats, given the deaths in younger rats and the lack of clinical safety and efficacy data in pediatric patients, avoid the use of IBSRELA in patients 6 years to less than 12 years of age.

Diarrhea Diarrhea was the most common adverse reaction in two randomized, double-blind, placebo-controlled trials of IBS-C. Severe diarrhea was reported in 2.5% of IBSRELA-treated patients. If severe diarrhea occurs, suspend dosing and rehydrate patient.

MOST COMMON ADVERSE REACTIONS The most common adverse reactions in IBSRELA-treated patients (incidence ≥2% and greater than placebo) were: diarrhea (16% vs 4% placebo), abdominal distension (3% vs <1%), flatulence (3% vs 1%) and dizziness (2% vs <1%).

INDICATION IBSRELA (tenapanor) is indicated for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adults.

Please see fullPrescribing Information, including Boxed Warning, for additional risk information.

IMPORTANT SAFETY INFORMATION (XPHOZAH)

CONTRAINDICATIONS XPHOZAH is contraindicated in:

  • Pediatric patients under 6 years of age

  • Patients with known or suspected mechanical gastrointestinal obstruction

WARNINGS AND PRECAUTIONS Diarrhea Patients may experience severe diarrhea. Treatment with XPHOZAH should be discontinued in patients who develop severe diarrhea.

MOST COMMON ADVERSE REACTIONS Diarrhea, which occurred in 43-53% of patients, was the only adverse reaction reported in at least 5% of XPHOZAH-treated patients with CKD on dialysis across trials. The majority of diarrhea events in the XPHOZAH-treated patients were reported to be mild-to-moderate in severity and resolved over time, or with dose reduction. Diarrhea was typically reported soon after initiation but could occur at any time during treatment with XPHOZAH. Severe diarrhea was reported in 5% of XPHOZAH-treated patients in these trials.

INDICATION XPHOZAH (tenapanor), 30 mg BID, is indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

For additional safety information, please see fullPrescribing Information.

About Ardelyx Ardelyx is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). The company’s pipeline includes the Phase 3 development of IBSRELA for chronic idiopathic constipation (CIC) and RDX10531, a next-generation NHE3 inhibitor with potential application across multiple therapeutic areas. Ardelyx works with partners to develop and commercialize its products outside of the United States. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.

Forward Looking Statements To the extent that statements contained in this press release are not descriptions of historical facts regarding Ardelyx, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Reform Act of 1995, including Ardelyx’s current expectations regarding: the long term potential for Ardelyx’s existing commercial products; our efforts towards profitability; opportunities for continued IBSRELA growth, including our expectation for achieving $1 billion in annual revenue; our U.S. net product sales revenue and operating expense guidance for full year 2026; our capital allocation strategy; the scope and duration of our intellectual property protection; and our expectations and timing regarding pipeline development activities, including the expected topline readout of the Phase 3 ACCEL trial. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control, that could cause actual outcomes or results to differ materially from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, Ardelyx’s ability to successfully commercialize IBSRELA and XPHOZAH; coverage and reimbursement decisions by government and commercial payors, including prior authorization and step-edit requirements; market acceptance of our products and the effectiveness of our commercial initiatives; competition, including from generic products; Ardelyx’s ability to achieve its financial guidance and long-term revenue expectations and reach profitability when anticipated; the timing, progress and results of clinical trials, including the ACCEL trial; the risk that real-world analyses may not predict future results or outcomes in broader patient populations; Ardelyx’s ability to obtain, maintain and enforce its intellectual property rights; reliance on third-party manufacturers and suppliers; and uncertainties regarding U.S. and foreign regulatory processes. Forward-looking statements speak only as of the date of this press release, and Ardelyx undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ardelyx’s business in general, please refer to Ardelyx’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 3, 2026, and its future current and periodic reports to be filed with the Securities and Exchange Commission.

Investor Contact: Lisa Caperelli SVP, Investor Relations & Corporate Communications [email protected]

| Ardelyx, Inc. Condensed Balance Sheets(Unaudited) (in thousands) |

| | | | |

| | September 30, 2026 | | December 31, 2025 |

| Assets | | | |

| Cash and cash equivalents | $ | 46,317 | | $ | 67,999 |

| Short-term investments | | 239,021 | | | 196,690 |

| Accounts receivable | | 93,441 | | | 71,848 |

| Prepaid commercial manufacturing | | 17,161 | | | 14,479 |

| Inventory | | 157,559 | | | 123,107 |

| Property and equipment, net | | 1,570 | | | 2,184 |

| Right-of-use assets | | 3,692 | | | 4,795 |

| Prepaid and other assets | | 28,764 | | | 20,502 |

| Total assets | $ | 587,525 | | $ | 501,604 |

| | | | |

| Liabilities and stockholders’ equity | | | |

| Accounts payable | $ | 33,657 | | $ | 19,235 |

| Accrued compensation and benefits | | 17,592 | | | 19,108 |

| Current portion of operating lease liability | | 1,579 | | | 1,479 |

| Deferred revenue | | 19,196 | | | 14,905 |

| Accrued expenses and other liabilities | | 71,880 | | | 51,218 |

| Long-term debt | | 252,360 | | | 202,834 |

| Deferred royalty obligation related to the sale of future royalties | | 27,215 | | | 25,876 |

| Total stockholders’ equity | | 164,046 | | | 166,949 |

| Total liabilities and stockholders’ equity | $ | 587,525 | | $ | 501,604 |

| | | | | | |

| Ardelyx, Inc. Condensed Statements of Operations(Unaudited) (in thousands, except share and per share amounts) |

| | | | |

| | Three Months Ended September 30, | | Nine Months Ended September 30, |

| | | 2026 | | | | 2025 | | | | 2026 | | | | 2025 | |

| Revenues | | | | | | | |

| Product sales, net | | | | | | | |

| IBSRELA | $ | 96,286 | | | $ | 78,158 | | | $ | 252,603 | | | $ | 187,606 | |

| XPHOZAH | | 29,169 | | | | 27,357 | | | | 84,354 | | | | 75,800 | |

| Total product sales, net | | 125,455 | | | | 105,515 | | | | 336,957 | | | | 263,406 | |

| Product supply revenue | | 1,380 | | | | — | | | | 3,710 | | | | 6,439 | |

| Licensing revenue | | 216 | | | | 25 | | | | 363 | | | | 5,065 | |

| Non-cash royalty revenue related to the sale of future royalties | | 604 | | | | 4,789 | | | | 1,975 | | | | 7,195 | |

| Total revenues | | 127,655 | | | | 110,329 | | | | 343,005 | | | | 282,105 | |

| Costs and operating expenses | | | | | | | |

| Cost of sales(1) | | 4,539 | | | | 3,982 | | | | 15,109 | | | | 28,688 | |

| Research and development | | 25,199 | | | | 18,067 | | | | 71,490 | | | | 48,671 | |

| Selling, general and administrative | | 93,894 | | | | 83,612 | | | | 297,601 | | | | 250,822 | |

| Total costs and operating expenses | | 123,632 | | | | 105,661 | | | | 384,200 | | | | 328,181 | |

| Income (loss) from operations | | 4,023 | | | | 4,668 | | | | (41,195 | ) | | | (46,076 | ) |

| Interest expense | | (5,880 | ) | | | (5,796 | ) | | | (16,436 | ) | | | (14,343 | ) |

| Non-cash interest expense related to the sale of future royalties | | (1,502 | ) | | | (2,188 | ) | | | (4,086 | ) | | | (6,478 | ) |

| Other income, net | | 2,712 | | | | 2,449 | | | | 6,862 | | | | 6,667 | |

| Loss before provision for income taxes | | (647 | ) | | | (867 | ) | | | (54,855 | ) | | | (60,230 | ) |

| Provision for income taxes | | 90 | | | | 102 | | | | 208 | | | | 962 | |

| Net loss | $ | (737 | ) | | $ | (969 | ) | | $ | (55,063 | ) | | $ | (61,192 | ) |

| Net loss per share of common stock - basic and diluted | $ | (0.00 | ) | | $ | (0.00 | ) | | $ | (0.22 | ) | | $ | (0.25 | ) |

| Shares used in computing net loss per share - basic and diluted | | 250,007,187 | | | | 241,908,407 | | | | 247,991,715 | | | | 240,165,744 | |

| | | | | | | | |

| (1) Prior year amounts have been reclassified to conform to the current year presentation. |

Primary Logo

Source: Ardelyx, Inc.

October 23, 2026

PDF Version

Real-world analysis showed serum phosphate reductions following XPHOZAH initiation across all phosphate binder groups evaluated

Additional data highlighted the challenges of managing hyperphosphatemia and the morbidity and mortality risks associated with long-term elevated phosphorus

WALTHAM, Mass., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced results from a real-world analysis presented at the American Society of Nephrology (ASN) Kidney Week 2026 evaluating real-world serum phosphate outcomes among adults on dialysis who initiated XPHOZAH either without a phosphate binder or as add-on therapy to a single phosphate binder. Ardelyx also presented data on the challenges patients experience in managing hyperphosphatemia, as well as the association between long-term hyperphosphatemia and serious health outcomes in patients on dialysis, including morbidity and mortality.

"These findings add meaningful real-world evidence describing serum phosphate reductions following XPHOZAH initiation in patients both with and without a phosphate binder at baseline," said Rajani Dinavahi, MD, Chief Medical Officer of Ardelyx. "The broader research we presented at ASN Kidney Week also highlights how persistently difficult it is for patients to manage hyperphosphatemia, and the serious mortality and morbidity risks associated with cumulative phosphate burden. Taken together, these data reinforce the ongoing challenges of phosphate management and why we need more treatment options to help patients on dialysis gain control of their phosphate levels "

The real-world analysis looked at serum phosphate outcomes in more than 1,400 adults on dialysis with hyperphosphatemia who started tenapanor either without a phosphate binder or alongside a single phosphate binder. Across all treatment groups, serum phosphate levels declined over six months of follow-up, with adjusted mean reductions at month six ranging from 0.80 to 1.55 mg/dL. The adjusted probability of reaching a serum phosphate level below 5.5 mg/dL ranged from 16% to 41% across groups, and 60% to 70% of patients remained on tenapanor at 180 days. The probability of remaining on tenapanor at 180 days was comparable across phosphate-binder groups. Overall, similar serum phosphate reductions were observed across the phosphate-binder groups evaluated, including among patients who initiated tenapanor without a phosphate binder.

Presentations at ASN 2026 include:

| Presentation Title | Authors | Poster Number | Presentation Details |

| Real-World Effectiveness of Tenapanor: Serum Phosphate Outcomes by Existing Phosphate Binder Use | Alan Fossa, Dhajanae Sylvertooth, Angelo Karaboyas, Roberto Pecoits-Filho, Luisa L. Scott | FR-PO0317 | Poster, Oct 23, 10:00 AM to 12:00 PM MDT |

| Patient Perspectives on Hyperphosphatemia Management in a Contemporary End-Stage Kidney Disease Cohort: Results of an Online Survey | Nissreen Elfadawy, Jaime Uribarri, Janet Diaz-Martinez, Asa Renfroe, Emily Belcher, Luisa L. Scott | FR-PO0324 | Poster, Oct 23, 10:00 AM to 12:00 PM MDT |

| Morbidity and Mortality Risks Associated with Cumulative Hyperphosphatemia in a Contemporary Cohort of US Dialysis Patients | Julia Scialla, Bernard Jaar, Nan Ji, Roberto Pecoits-Filho, Keith McCullough, Luisa L. Scott | FR-PO0316 | Poster, Oct 23, 10:00 AM to 12:00 PM MDT |

The posters are available on the ASN Kidney Week 2026 website here.

About XPHOZAH® (tenapanor) XPHOZAH® (tenapanor) is the first and only phosphate absorption inhibitor (PAI) approved by the U.S. Food and Drug Administration to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. With a differentiated mechanism of action, XPHOZAH blocks phosphate absorption through the paracellular pathway, the primary pathway of phosphate absorption, and is administered as one tablet taken twice daily. Diarrhea was the most common side effect experienced by patients taking XPHOZAH in clinical trials. Please see Important Safety Information below and click for full Prescribing Information.

About Hyperphosphatemia Hyperphosphatemia is a serious condition characterized by elevated levels of phosphate in the blood that affects many of the approximately 550,000 people in the United States with chronic kidney disease (CKD) on maintenance dialysis. As kidney function declines, the kidneys are unable to adequately eliminate excess phosphate, leading to its accumulation in the blood. Elevated phosphate levels are associated with adverse clinical outcomes in patients with CKD on dialysis. International KDIGO treatment guidelines recommend lowering progressively or persistently elevated serum phosphate toward the laboratory-specific normal range. In adults, a commonly used reference range is approximately 2.5–4.5 mg/dL.

IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS XPHOZAH is contraindicated in:

  • Pediatric patients under 6 years of age

  • Patients with known or suspected mechanical gastrointestinal obstruction

WARNINGS AND PRECAUTIONS Diarrhea Patients may experience severe diarrhea. Treatment with XPHOZAH should be discontinued in patients who develop severe diarrhea.

MOST COMMON ADVERSE REACTIONS Diarrhea, which occurred in 43-53% of patients, was the only adverse reaction reported in at least 5% of XPHOZAH-treated patients with CKD on dialysis across trials. The majority of diarrhea events in the XPHOZAH-treated patients were reported to be mild-to-moderate in severity and resolved over time, or with dose reduction. Diarrhea was typically reported soon after initiation but could occur at any time during treatment with XPHOZAH. Severe diarrhea was reported in 5% of XPHOZAH-treated patients in these trials.

INDICATION XPHOZAH (tenapanor), 30 mg BID, is indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

For additional safety information, please see full Prescribing Information.

About Ardelyx Ardelyx is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). The company’s pipeline includes the Phase 3 development of IBSRELA for chronic idiopathic constipation (CIC) and RDX10531, a next-generation NHE3 inhibitor with potential application across multiple therapeutic areas. Ardelyx works with its partners to develop and commercialize its products outside of the United States. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.

Forward Looking Statements To the extent that statements contained in this press release are not descriptions of historical facts regarding Ardelyx, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Litigation Reform Act of 1995, including Ardelyx’s current expectations regarding: the presentation sessions at ASN Kidney Week 2026, including their timing and content; any clinical implications of the real-world or other analyses described in this press release; and our ongoing development programs. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control, that could cause actual outcomes or results to differ materially from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, uncertainties associated with the development of, regulatory process for, and commercialization of drugs in the U.S. and internationally, and the risk that real-world, post hoc, observational, survey or other analyses may not be indicative of future results or outcomes in broader patient populations, or may be interpreted differently by others. Ardelyx undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ardelyx’s business in general, please refer to Ardelyx's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2026, and its future current and periodic reports to be filed with the Securities and Exchange Commission.

Investor Contact: Lisa Caperelli SVP, Investor Relations & Corporate Communications [email protected]

Media Contact: Lindsey Manuel Associate Director, Corporate Communications [email protected]

Primary Logo

Prompts

Ardelyx, Inc. (ticker ARDX), listed in United States.

ETFs Holding Ardelyx, Inc.

ETF Weight in ETF Shares Market value As of
ESSC 0.16% 11,542 $ 57.133K Jul 31, 2026
FSML 0.07% 16,081 $ 82.013K Jun 30, 2026
FSEG 0.06% 668 $ 3,406.80 Jun 30, 2026
RESM 0.04% 276 $ 1,407.60 Jun 30, 2026
MSSM 0.00% 9,142 $ 34.557K Aug 31, 2026
FESM 0.00% 45,819 $ 233.677K Jun 30, 2026